Yakovtsova I. I., Yakymenko A. S., Ivakhno I. V., Danyliuk S. V.

PATHOMORPHOLOGY

Scentific article

Epithelial-mesenchymal transformation (EMT) is a prognostic criteria of colorectal carcinoma (CRC). However, its accounting has not been widely used in clinical practice. There is also no information about stages of EMT as a prognostic criteria of CRC. The aim of the research was to investigate the prognostic criteria of recurrence and lethal outcome of CRR IIA and IIIB stages. Material and Methods. The group I was formed from primary CRC without recurrences. The ІІ group – primary CRC with recurrences; ІІА – with recurrences during 5 years from the moment when the tumor was removed, without fatal outcome; ІІВ – with recurrences and fatal outcome from generalization of tumor process during 5 years from lethal outcome from the moment when the tumor was removed. The ratio of tumors with certain differentiation in groups of research was taken equal. Immunohistochemical study was performed using monoclonal antibodies to vimentin, CC20, E- and N-cadherin. Taking into account the coexpression of markers allowed to determine the stages of EMT. Results. Molecular biological signs of EMT were observed in 53.3% (32/60) of CRC stage IIA-IIIB, its appearance was associated with G3 differentiation (p<0.03). Also, CRC G3 was characterized by a higher stage of EMT in comparing with CRC G1-2 (p<0,05). The appearance of EMT was associated with recurrence of CRC (p<0.01), there is a tendency of increasing the stage of EMT among recurrent CRC, mainly due to a subgroup of recurrent with lethal outcome. The appearance of EMT was a prognostic criterion of recurrence free survival (RFS). According to the data received, the rate of RFS in patients with EMT of CRC was lower (p<0.001). Thus, the average recurrence period among those without EMT was 25.7±3.9, among CRC with EMT – 17.4±2.7 months. An inverse correlation was also observed between the recurrence period and the EMT stage (r=-0.42, p<0.01). There is a tendency to a greater number of cases of CRC stage 3-4 EMT among patients with recurrence and death (p>0.05). Conclusions. EMT is a prognostic criterion for recurrence and recurrence time of CRP pT3N0-2M0, more common in tumors of patients with recurrence and death.

EMT, colorectal cancer, recurrence, prognosis.

1. Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Ann Transl Med. 2019 Nov;7(21):609. DOI: 10.21037/atm. 2019.07.91.
2. Ryuk JP, Choi GS, Park JS, Kim HJ, Park SY, Yoon GS, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res. 2014 Mar;86(3):143-51. DOI: 10.4174/astr.2014.86.3.143.
3. Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med. 2015 Mar 15;8(3):3707-15.
4. Poornakala S, Prema NS. A study of morphological prognostic factors in colorectal cancer and survival analysis. Indian J Pathol Microbiol. 2019 Jan-Mar;62(1):36-42. DOI: 10.4103/IJPM.IJPM_91_18.
5. Konishi T, Shimada Y, Lee LH, Cavalcanti MS, Hsu M, Smith JJ, et al. Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers. Am J Surg Pathol. 2018;42(6):705-714. DOI: 10.1097/ PAS.0000000000001059.
6. Guo TA, Wu YC, Tan C, Jin YT, Sheng WQ, Cai SJ, et al. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. Int J Cancer. 2019 Sep 15;145(6):1625-1634. DOI: 10.1002/ijc. 32489.
7. Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A, et al. Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2013 Nov;34(11):2548-57. DOI: 10.1093/ carcin/bgt282.
8. Vu T, Datta PK. Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis. Cancers (Basel). 2017 Dec 16;9(12):171. DOI: 10.3390/ cancers 9120171.
9. Niknami Z, Muhammadnejad A, Ebrahimi A, Harsani Z, Shirkoohi R. Significance of E-cadherin and Vimentin as epithelial-mesenchymal transition markers in colorectal carcinoma prognosis. EXCLI J. 2020 Jun 26;19:917-926. DOI: 10.17179/excli2020-1946.
10. Zhang Z, Zheng S, Lin Y, Sun J, Ding N, Chen J, et al. Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients. BMC Cancer. 2020 Nov 23;20(1):1135. DOI: 10.1186/s12885-020-07615-5.
11. Vogel JD, Eskicioglu C, Weiser MR, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Colon Cancer. Dis Colon Rectum. 2017 Oct;60(10):999-1017. DOI: 10.1097/DCR.0000000000000926.
12. Al-Maghrabi J. Vimentin immunoexpression is associated with higher tumor grade, metastasis, and shorter survival in colorectal cancer. Int J Clin Exp Pathol. 2020 Mar 1;13(3):493-500.
13. Wong SHM, Fang CM, Chuah LH, Leong CO, Ngai SC. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018 Jan;121:11-22. DOI: 10.1016/j.critrevonc.2017.11.010.
14. Bryan RT. Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena. Philos Trans R Soc Lond B Biol Sci. 2015 Feb 5;370(1661):20140042. DOI: 10.1098/rstb.2014.0042.
15. Roseweir AK, Kong CY, Park JH, Bennett L, Powell AGMT, Quinn J, et al. A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. Int J Cancer. 2019 Jan 1;144(1):150-159. DOI: 10.1002/ijc.31739.
16. Wang Y, Wu Z, Hu L. Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II. Gastroenterol Res Pract. 2017;2017:2520581. DOI: 10.1155/ 2017/2520581.

«Bulletin of problems biology and medicine» Issue 4 (162), 2021 year, 297-301 pages, index UDK 616.34/.35-006.6-076-091.8

10.29254/2077-4214-2021-4-162-297-301